trending Market Intelligence /marketintelligence/en/news-insights/trending/xibjfwtlgomelwgys81umg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

I-O company Surface Oncology files for IPO, to raise $11.5M in placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

I-O company Surface Oncology files for IPO, to raise $11.5M in placement

Cambridge, Mass.-based Surface Oncology Inc. filed for an IPO of its common stock, hoping to raise up to $75 million.

The immuno-oncology company plans to list its shares on the Nasdaq Global Market under the symbol SURF.

Goldman Sachs & Co. LLC and Cowen and Co. LLC are acting as the representatives of the underwriters for the offering.

Meanwhile, Novartis Institutes for BioMedical Research Inc. — a unit of Novartis AG — also agreed to buy $11.5 million worth of Surface Oncology shares in a concurrent private placement.

Surface plans to use the net proceeds from the IPO and the placement for operating expenses and capital expenditure requirements.

Surface Oncology develops cancer therapies by adjusting a patient's immune system to fight cancer.